does dpp 4 break down glp-1 Potential mechanisms of action of dipeptidyl peptidase on bone Clinical Use of DPP-4 Inhibitors

He Z, et al

report side effects via the MHRA Yellow Card Scheme and never stop treatment without medical advice

According to NICE guidance and MHRA safety information, healthcare professionals should maintain vigilance for rare but serious adverse effects including acute pancreatitis, gallbladder disease, and potential thyroid tumours (based on animal studies, though human risk remains uncertain)

Two people can lose the exact same amount of weight on the scale, but have very different outcomes depending on how much muscle they preserved along the way

Some of the claims are verifiable through the sites Press & Media section, but others lack a direct source to check